Information  X 
Enter a valid email address

Open Orphan PLC (ORPH)

  Print      Mail a friend

Thursday 16 January, 2020

Open Orphan PLC

Schedule One Update

RNS Number : 0696A
Open Orphan PLC
16 January 2020
 

Pre-Admission Announcement
Euronext Growth Schedule 1

Announcement to be made by the Applicant prior to admission in accordance with the Euronext Growth Markets Rule Book

All Applicants must complete the following

Company name  

Open Orphan plc ("Open Orphan" or the "Company", and together with its subsidiaries the "Group")

 

 

Company registered address and if different, company trading address (including postcodes)

 

Registered Office:

 

PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ

 

Trading Offices:

 

19 Railway Road, Dalkey, Dublin, Ireland

Queen Mary BioEnterprises (QMB) Innovation Centre, 42 New Road, London, E1 2AX

 

 

Country of incorporation  

 

England and Wales

   

 

Company website address containing all information required by rule 26 (5.26) of the Euronext Growth Markets Rule Books

www.openorphan.com

 

Company business (including main country of operation) or, in the case of an investing company, details of its investing strategy. If the admission is sought as a result of a reverse takeover under rule 5.19 of the Euronext Growth Markets Rule Books, this should be stated

 

This is a reverse takeover under Rule 14.

 

Open Orphan is a Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in the UK, France, the Netherlands and Germany.

 

 

Details of securities to be admitted including any restrictions as to transfer of securities (i.e. where known, number of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

 

Number of ordinary shares of 0.1 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 445,622,374

 

There are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury.

 

 

     

 

Capital to be raised on admission (if applicable) and anticipated market capitalisation on admission:

Expected Market Capitalisation: £29.6 million (based on an enlarged share capital of 445,622,374 and closing price per Open Orphan Shares of £[0.0665] on 15 January 2020)

 

No capital to be raised on admission

 

 

 

Percentage of Euronext Growth securities not in public hands on admission

 

22.8%

 

Details of any other exchange or trading platform to which the ex securities (or other securities of the company) are or will be admitted or traded:

 

AIM

 

 

Full names and functions of directors and proposed directors (underlining the first name by which each is known or including any other name by which each is known):

 

Directors:

Cathal Friel, Executive Chairman

Brendan Buckley, Non-executive Director

 

Proposed Directors:

Dr Trevor Phillips, Chief Executive Officer

Dr Mark Warne, Non-executive Director

Michael Meade, Non-executive Director

 

 

 

Full names and holdings of significant shareholders, expressed as a percentage of the issued share capital, before or after admission (underlining the first name by which each is known or including any other name by which each is known):

Before Admission:

 

Name

Number of Ordinary Shares

Percentage of issued share capital

Cathal Friel

41,046,981

16.1%

Anthony (Tony) Richardson

16,313,388

6.4%

Gresham House Asset Management

13,081,337

5.1%

Crux Asset Management

11,928,571

4.7%

Brendan Buckley

7,845,860

3.1%

 

After Admission:

 

Cathal Friel

41,046,981

9.2%

Anthony (Tony) Richardson

16,313,388

3.7%

Gresham House Asset Management

13,081,337

2.9%

Crux Asset Management

11,928,571

2.7%

Brendan Buckley

7,845,860

1.8%

Invesco Ltd

52,485,973

11.8%

Link Fund Solutions Ltd

38,618,608

8.7%

IP Group plc

32,267,791

7.2%

Jupiter Asset Management Ltd

22,819,579

5.1%

 

 

Names of all persons to be disclosed in accordance with Chapter 5: Schedule Two, paragraph (h) of the Euronext Growth Markets Rule Book:

n/a

i       anticipated accounting reference date: 31 December

 

ii      date to which the main financial information in the admission document has been prepared:  31 December 2019

 

 

iii. dates by which it must publish its first three reports pursuant to Rules 5.14 and 5.15 in the Euronext Growth Markets Rule Book:

 

31 December 2019 due 30 June 2020, 30 June 2020 due September 2020, 31 December 2020 due 30 June 2021

 

 

Expected admission date:  20 January 2020

 

 

Name and address of Euronext Growth Advisor

 

Davy Corporate Finance, Davy House, 49 Dawson Street, Dublin 2, Ireland

 

 

Name and address of broker

 

 

Arden Partners plc., 125 Old Broad Street, London, EC2N 1AR

 

Other than in the case of a Quoted Applicant, details of where (postal or internet address) the admission document will be available from, with a statement that this will contain full details about the Applicant and the admission of its securities

 

A copy of the admission document containing full details about the applicant and the admission of its securities is available on the Company's website, www.openorphan.com

 

Date of notification 

16 January 2020

 

 

 

New/update: Update

 

       

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFEVLTIRLII

a d v e r t i s e m e n t